Novartis Unveils Positive Phase II Results For Genetic Auto-inflammatory Disease Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Interleukin 1b blocker ACZ885 achieves complete clinical remission in seven days for Cryopyrin-Associated Periodic Syndrome Patients.
You may also be interested in...
Novartis Moves Up First Filing For Auto-Inflammatory Drug ACZ885 In Cryopyrin-Associated Syndromes
Canakinumab showcases Novartis Institute for Biomedical Research’s novel subpopulaton proof-of-concept model.
Novartis Moves Up First Filing For Auto-Inflammatory Drug ACZ885 In Cryopyrin-Associated Syndromes
Canakinumab showcases Novartis Institute for Biomedical Research’s novel subpopulaton proof-of-concept model.
Drug Development Chief Departs Beleaguered Novartis
Trevor Mundel is set to replace James Shannon, Novartis confirms to “The Pink Sheet” DAILY.